Related Experiment Video

Updated: May 29, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Susceptibility genes for coronary heart disease and myocardial infarction

Ambrose Kibos1, Alejandra Guerchicoff

  • 1Department of Cardiology, Bathurst Regional Hospital Centre, New Brunswick, Canada. ambrose.samwel.kibos@umontreal.ca

Acute Cardiac Care
|September 1, 2011
PubMed

Insights

Genomic advances improve cardiovascular risk assessment beyond traditional models. New genetic markers and single nucleotide polymorphisms (SNPs) aid in early disease prediction and prevention strategies for better outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Genomics
  • Proteomics

Background:

  • Coronary heart disease (CHD) and myocardial infarction are leading global causes of death.
  • Pharmacotherapy for dyslipidemias, diabetes mellitus, and hypertension has improved survival.
  • Traditional risk factor scoring models need enhancement for accurate cardiovascular disease (CVD) risk identification.

Purpose of the Study:

  • To explore advancements in genomics, proteomics, and imaging for improved cardiovascular risk assessment.
  • To enhance understanding of disease pathology at the molecular level.
  • To facilitate earlier preventive strategies for cardiovascular outcomes.

Main Methods:

  • Leveraging progress in genomics, including the 2004 Human Genome Sequencing Consortium.
  • Utilizing proteomics and advanced imaging techniques.
  • Identifying genetic markers, single nucleotide polymorphisms (SNPs), and haplotype blocks.

Main Results:

  • Genomic advances offer deeper insights into cardiovascular pathology.
  • New molecular-level characterizations of disease are emerging.
  • Improved understanding facilitates better disease prediction.

Conclusions:

  • Genomics, proteomics, and imaging are revolutionizing cardiovascular risk assessment.
  • Identification of genetic markers like SNPs enhances predictive accuracy.
  • Earlier and more precise preventive strategies can improve cardiovascular outcomes.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...